Scarica l'app Stockscreener
26.01
3.49%
-0.94
Dopo l'orario di chiusura:
26.50
0.49
+1.88%
Ascentage Pharma Group International Adr Borsa (AAPG) Ultime notizie
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - GlobeNewswire Inc.
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownHere's Why - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Sees Significant Drop in Short Interest - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and Integra Lifesciences (IART) - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpHere's What Happened - MarketBeat
Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN
Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - TipRanks
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025 - The Globe and Mail
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LSX:A40ZYR - TradingView
ETFs Investing in Ascentage Pharma Group International Unsponsored ADR Stocks - TradingView — Track All Markets
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LS:A40ZYR - TradingView
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Ascentage Pharma Announces New RSU and Share Option Grants - TipRanks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial - Defense World
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Today | Live Chart & News - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 12.2%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks - TipRanks
Free cash flow per share of Ascentage Pharma Group International Unsponsored ADR – SWB:36X0 - TradingView
Ascentage Pharma to Engage Investors at November Conferences - TipRanks
Centurion Acquisition Corp. (NASDAQ:ALFUW) Short Interest Down 57.1% in October - Defense World
Zymeworks’ Promising FRa ADC Potential: Buy Rating Affirmed by Analyst - TipRanks
Revolution Medicines: Strong Buy Rating Driven by Innovative Oncology Advancements and Strategic Market Position - TipRanks
Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform - TipRanks
Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 3.5%Here's What Happened - MarketBeat
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV) - The Globe and Mail
Ascentage Pharma Engages Investors at October 2025 Conferences - TipRanks
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Up 70.0% in September - Defense World
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):